Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
Want to see LRMR full AI Analyst Report?
LRMR Stock Chart & Stats
$4.80
-$0.11(-2.78%)
At close: 4:00 PM EST
$4.80
-$0.11(-2.78%)
Day’s Range― - ―
52-Week Range$1.73 - $6.42
Previous CloseN/A
Volume147.46K
Average Volume (3M)1.82M
Market Cap
$438.39M
Enterprise Value$261.82M
Total Cash (Recent Filing)$136.85M
Total Debt (Recent Filing)$4.07M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
May 07, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding103,882,935
10 Day Avg. Volume1,412,543
30 Day Avg. Volume1,816,161
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.56
Price to Sales (P/S)0.00
P/FCF Ratio-2.45
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-999.32
Enterprise Value/Ebitda-1.54
Forecast
1Y Price Target
$13.90Price Target Upside189.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.96
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst SentimentAnalyst reiterates a Buy rating and views the stock as undervalued relative to precedent deals, implying meaningful upside if clinical and regulatory milestones are achieved.
Biomarker ValidationRegulatory acceptance of skin frataxin levels as a surrogate marker supports use of biomarker data in a submission and could streamline confirmatory trial endpoints.
Regulatory PathwayFDA Breakthrough Therapy designation and inclusion in the START program create a clearer pathway to expedited review and enable closer regulator communication, supporting a more efficient route to potential approval.
Bears Say
Development UncertaintyAnalyst's High Risk classification reflects substantial uncertainty around development and approval outcomes, which could materially affect valuation if trials fail to meet expectations.
Financial VulnerabilityWeak profitability metrics and limited book value per share highlight financial fragility that could put pressure on the stock absent clear revenue or successful funding events.
Safety RiskAnaphylactic reactions tied to nomlabofusp represent a significant clinical and regulatory concern that could limit prescribing and complicate labeling and uptake.
Larimar Therapeutics News
LRMR FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was $1.73 and its highest was $6.42 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Larimar Therapeutics, Inc.’s market cap is $438.39M.
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is May 07, 2026 which is tomorrow.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Larimar Therapeutics, Inc. released its earnings results on Mar 19, 2026. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.489 by -$0.241.
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -0.53.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 103,882,935 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Larimar Therapeutics, Inc. reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.489. Following the earnings report the stock price went up 3.953%.
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LRMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Larimar Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.90 (189.58% Upside)
$13.90 (189.58% Upside)
Blogger Sentiment
Bullish
LRMR Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 6.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
151.30%
12-Months-Change
Fundamentals
Return on Equity
-137.70%
Trailing 12-Months
Asset Growth
-27.11%
Trailing 12-Months
Company Description
Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
LRMR Stock 12 Month Forecast
Average Price Target
$13.90
▲(189.58% Upside)
Technical Analysis
Omeros
―
Vanda
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
35.94% Insiders
4.88% Mutual Funds
3.02% Other Institutional Investors
49.87% Public Companies and Individual Investors